|Bid||17.32 x 4000|
|Ask||17.39 x 800|
|Day's Range||17.10 - 17.38|
|52 Week Range||12.89 - 21.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.88|
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Wall Street closed up on Thursday as tech shares rallied and trade tensions eased on the hopes of a fresh round of trade talks, that could potentially take ...
Ironwood, which is one of the state's biggest life sciences employers, announced earlier this year that it plans to split into separate businesses.
Ironwood Pharmaceuticals, Inc. (IRWD), a commercial biotech company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for praliciguat (IW-1973) for the treatment of patients with heart failure with preserved ejection fraction (HFpEF). Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A live webcast of Ironwood’s presentations will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist “Linzess® Tablets 0.25 mg (generic name: linaclotide)” for the additional indication of chronic constipation (other than constipation associated with organic disorders1) (“chronic constipation”). Linzess® Tablets 0.25 mg were licensed from Ironwood and have been developed and commercialized in Japan by Astellas.
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
NEW YORK, Aug. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omnicom ...
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Ironwood (IRWD) delivered earnings and revenue surprises of -47.37% and -9.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for amortization costs and non-recurring costs, came to 28 cents per share. The results fell short ...
– Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® U.S. net sales of $192 million and commercial margin of 60% –
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Ironwood Pharmaceuticals, Inc. Class A (NASDAQ: IRWD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 8:30 ...
Short interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding IRWD totaled $454 million.
Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its second quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 6, 2018. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 5795089. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.